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Abstract
Background: Visceral adiposity index (VAI) has recently been suggested to be used as a surrogate of visceral
adiposity. We examined if VAI could improve predictive performances for CVD of the Framingham’s general CVD
algorithm (a multivariate model incorporating established CVD risk factors). We compared the predictive abilities of
the VAI with those of simple anthropometric measures i.e. BMI, waist-to-height ratio (WHtR) or waist-to-hip ratio
(WHpR).
Design and methods: In a nine-year population-based follow-up, 6 407 (2 778 men) participants, free of CVD at
baseline, aged ≥ 30 years were eligible for the current analysis. The risk of CVD was estimated by incorporating VAI,
BMI, WHpR, and WHtR, one at a time, into multivariate accelerated failure time models.
Results: We documented 534 CVD events with the annual incidence rate (95%CIs) being 7.3 (6.4-8.3) among
women and 13.0 (11.7-14.6) among men. Risk of future CVD increased with increasing levels of VAI among both
men and women. VAI was associated with multivariate-adjusted increased risk of incident CVD among women.
However, the magnitude of risk conferred by VAI was not significantly higher than those conferred by BMI, WHpR,
or WHtR. Among men, after adjustment for established CVD risk factors, VAI was no longer associated with
increased risk of CVD. VAI failed to add to the predictive ability of the Framingham general CVD algorithm.
Conclusions: Using VAI instead of simple anthropometric measures may lead to loss of much information needed
for predicting incident CVD.
Keywords: Body mass index, Cardiovascular disease, Prediction, Visceral adiposity index, Waist- to-height ratio,
Waist-to-hip ratio
Introduction
There is no consensus on the definition of obesity or on
specific aspects of obesity that contribute to the risk of
CVD [1]. The precise measurement of the total amount of
body fat and its regional distribution is possible by using
computed tomography (CT), dual-energy X-ray absorption
[2]. Magnetic resonance imaging (MRI), like CT, can sepa-
rate visceral fat from subcutaneous fat and since there is
no radiation involved, it can perform a total body scan for
maximal accuracy and fat distribution. However, these
methods are primarily used at the research level. Besides,
they are time-consuming, costly, and not routinely avail-
able. Accordingly there is a need for simple techniques
that can discriminate regional fat. Amato et al. have
recently individuated a novel sex-specific index based on
waist circumference, body mass index (BMI), triglycerides
(TGs), high-density lipoprotein cholesterol (HDL-C), and
indirectly expressing visceral fat [3] and termed it the visc-
eral adiposity index (VAI). VAI had significant correlation
with visceral adiposity and its increase was strongly asso-
ciated with cardiometabolic risk. However, the prospective
relation between VAI and CVD is less clear [3]. Clinical
importance of visceral adiposity lies in its association with
health risks like CVD. Therefore, from clinical point-of-
view, indices developed to measure visceral adiposity
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risks known to be associated with it [4,5].
Using data from a large community-based study, we
examined if VAI would improve CVD prediction currently
made by multivariate algorithms and if VAI could add to
the predictive ability of the simple anthropometric mea-
sures of adiposity i.e. BMI, waist-to-height ratio (WHtR)
or waist-to-hip ratio (WHpR).
Methods
Study population
Detailed descriptions of the Tehran lipid and glucose
study (TLGS) have been reported elsewhere [6]; in brief,
the TLGS is a large scale, long term, community-based
prospective study performed on a representative sample of
residents of district 13 of Tehran, the capital of Iran. The
TLGS has two major components: a cross-sectional preva-
lence study of noncommunicable disease and associated
risk factors, implemented between March 1999 and
December 2001, and a prospective follow-up study. Data
collection is ongoing, designed to continue for at least 20
years, at 3-year intervals. Participants were categorized
into the cohort (n = 9375) and intervention groups (n =
5630), the latter to be educated for implementation of life
style modifications. For the current study, among partici-
pants aged ≥ 30 (n = 8,071), we selected those who partici-
pated in the follow-up study until 20 March 2009 (n =
7,154). After exclusions (344 prevalent CVD and 382 miss-
ing data), 6,407 (2,778 men) participants remained eligible
(response rate 95%), contributing to a 54,950 person-year
follow up. At the time of this study, the median follow up
time was 9.1 years. Participants were provided with infor-
mation regarding the results of their examinations and
were given appropriate medical advice.
Clinical and laboratory measurements
Using a pretested questionnaire, a trained interviewer col-
lected information on demographic data, family history of
premature CVD, past medical history of CVD, and smok-
ing status. Detailed description of clinical and laboratory
measurements has been provided in appendices. Weight
was measured, with subjects minimally clothed without
shoes, using digital scales (Seca 707: range 0.1-150 kg) and
recorded to the nearest 100 g. Height was measured in a
standing position without shoes, using tape meter while
shoulders were in a normal alignment. Waist circumfer-
ence (WC) was measured at the umbilical level and that of
the hip at the maximum level over light clothing, using an
unstretched tape meter, without any pressure to body sur-
face and measurements were recorded to the nearest
0.1 cm [7]. BMI (kg.m
-2) was calculated as weight (kg)
divided by square of the height (m
2). WHpR was calcu-
lated as WC (cm) divided by hip circumference (cm) and
WHtR was calculated as WC divided by height (cm). After
a 15-minute rest in the sitting position, two measurements
of blood pressure were taken, on the right arm, using a
standardized mercury sphygmomanometer (calibrated by
the Iranian Institute of Standards and Industrial
Researches); the mean of the two measurements was con-
sidered as the participant’s blood pressure.
A blood sample was drawn between 7:00 and 9:00 AM
from all study participants, after 12 to 14 hours overnight
fasting. All the blood analyses were undertaken at the
TLGS research laboratory on the day of blood collection.
Plasma glucose was measured using an enzymatic colori-
metric method with glucose oxidase. Fasting plasma
glucose (FPG) measurement was performed for all parti-
cipants, and the standard 2-hour post-challenge plasma
glucose (2 h-PCPG) test for those not on glucose-lower-
ing drugs. Total cholesterol (TC) was assayed, using the
enzymatic colorimetric method with cholesterol esterase
and cholesterol oxidase. High-density lipoprotein choles-
terol (HDL-C) was measured after precipitation of the
apolipoprotein B containing lipoproteins with phospho-
tungistic acid. TGs were assayed using enzymatic colori-
metric assay with glycerol phosphate oxidase. Analyses
were performed using Pars Azmon kits (Pars Azmon
Inc., Tehran, Iran) and a Selectra 2 auto-analyzer (Vital
Scientific, Spankeren, Netherlands). All samples were ana-
lyzed when internal quality control met the acceptable
criteria. The intra and inter-assay coefficients of variation
were both < 2.2% for plasma glucose, and 0.5 and 2% for
TC, respectively [6].
Outcome measurements
Details of cardiovascular outcomes have been published
elsewhere [8]. In this ongoing study every TLGS’ partici-
pant is followed up for any medical event during the pre-
vious year, by telephone. They are questioned by a trained
nurse regarding any medical conditions or whether a
related event have occurred, a trained physician collects
complementary data during a home visit and a visit to the
respective hospital to collect data from the participants
medical files. In the case of mortality, data are collected
from the hospital or the death certificate by an authorized
local physician. Collected data are evaluated by an out-
come committee consisting of a principal investigator, an
internist, an endocrinologist, a cardiologist, an epidemiolo-
gist, and the physician who collects the outcome data.
Other experts are invited for evaluation of non-commu-
nicable disorders, as needed. A specific outcome for each
event is assigned according to International Statistical
Classification of Diseases and Related Health Problems cri-
teria (10th Revision), and the American Heart Association
classification for cardiovascular events [6,9,10]. Coronary
heart disease (CHD) includes cases of definite myocardial
infarction (MI) diagnosed by electrocardiogram (ECG) and
biomarkers, probable MI (positive ECG findings plus
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tive or equivocal results), unstable angina pectoris (new
cardiac symptoms or changing symptom patterns and
positive ECG findings with normal biomarkers), angio-
graphic proven CHD and CHD death. CVD is specified as
a composite measure of any CHD events, stroke, or cere-
brovascular death.
Definition of terms
Following Amato et al. [3] we defined VAI as:
Males =

WC
39.68 + 1.88 × BMI

×

TGs
1.03

×

1.31
HDL - C

Females =

WC
36.58 + 1.89 × BMI

×

TGs
0.81

×

1.52
HDL - C

assuming VAI = 1 in healthy non-obese subjects with
normal adipose distribution and normal TG and HDL
levels. A previous history of CVD reflected any prior
diagnosis of CVD by a physician. A current smoker was
defined as a person who smokes cigarettes daily or occa-
sionally. Participants using oral hypoglycemic agents or
insulin were considered as having diabetes. Diabetes was
also ascertained in participants with FPG ≥ 7.0 mmol.l
-1
or 2 h-PCPG ≥ 11.1 mmol.l
-1 [11]. Non-HDL-C was cal-
culated by subtracting HDL-C from total cholesterol.
For each participant, free of CVD at baseline, the base-
line risk of CVD was calculated by re-estimating the
Framingham’s “general CVD risk prediction algorithm
[12].
Statistics analysis
Findings on covariate variables are expressed as means
(SD) or percentages for continuously distributed and cate-
gorical variables, respectively. We tested for trends across
VAI quintiles by using the median in each quartile as a
predictor, separately for each sex. Statistical significance in
trends was examined by implementing General Linear
Models. The Log-Rank test and Cox test were used to
examine the significance of trends in incident rates and
survivor functions.
In the analysis of CVD outcome, VAI, BMI, WHpR and
WHtR were assessed using accelerated failure time
method: Weibull survival regression model. Survival time
was the time from start of the follow-up period to the
date of the first incident, CVD event (failure). The cen-
soring time of an individual was the time from entry into
the study to loss to follow-up or the end of the study,
whichever happened first. Censored observation meant
the individuals either refused to participate further in the
study (lost to follow-up), died (from none-CVD causes),
when death was not the study outcome (competing risk)
or continued until the study was ended (administrative
censoring). Valid comparison of hazards ratios (HRs) for
different continuous measures requires that the units of
both variables to be comparable. We, thus, estimated
sex-specific age-adjusted hazard ratios (HRs), with 95%
confidence intervals (CI) for CVD events for a one-SD
increment in VAI and each respective anthropometric
parameter. We controlled our regression analyses for
cofounding bias due to potential confounders i.e. age,
systolic blood pressure, using antihypertensive drugs,
total and HDL cholesterol, diabetes and smoking [13].
We compared predictive performance of the VAI with
those of the studied anthropometric variables in terms
of the effect size (HR), calibration and discrimination,
added predictive ability, and explained variation.
Wald tests of the linear hypotheses concerning the Wei-
bull survival regression models coefficients (paired homo-
geneity test) were performed to test the null hypotheses
that the hazard ratios (effect size) for VAI were equal to
those for anthropometric measures. We assessed collinear-
ity of BMI, WHpR, and WHtR, with VAI using variance
inflation factor (VIF). VIFs > 10 warrant caution [14].
Calibration, as it is phrased in reference [15] describes
how closely predicted probabilities agree numerically
with actual outcomes [16,17]. A test very similar to the
Hosmer-Lemeshow test has been proposed by Nam and
D’Agostino. We calculated the NamD’Agostino c
2 to
examine calibration for prediction models [15]. As sug-
gested by D’Agostino and Nam, calibration chi-square
values greater than 20 (P < 0.01) suggest lack of adequate
calibration [15].
Discrimination is the ability of a prediction model to
separate those who develop incident CVD events from
those who do not and is quantified by the Harrell’s C
statistic [18]. In the survival analysis, C statistic [19]
measures the probability that a randomly selected per-
son who developed an event, at the certain specific time
has a higher risk score than a randomly selected person
who did not develop an event during the same, specific
follow-up interval [20].
Discriminations measures are not sensitive to changes
in absolute risk [21]. We, thus, calculated absolute and
relative integrated discrimination improvement index
(IDI) and cut-point-based and cut-point-free net reclas-
sification improvement index (NRI). IDI and NRI are
measures of predictive ability added to an old model by
a newer one [21]. Bootstrapping method was implemen-
ted in order to obtain bias-corrected 95% confidence
intervals (95% CIs).
We hereby certify that all applicable institutional and
governmental regulations concerning the ethical use of
human volunteers were followed during this research.
Informed written consent was obtained from all partici-
pants and the Ethical Committee of Research Institute
for Endocrine Sciences approved this study.
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type I error of 0.05. All statistics analyses were per-
formed using STATA version 12 (STATA, College
Station, Texas USA) and SAS 9.2 (SAS Institute Inc.,
Cary, NC, USA).
Results
For a median follow up of 9 years, 6,407 (3,629 women)
adult participants of the TLGS contributed to a total of
54,950 person-years follow up. We documented 534
CVD events with the annual incidence rate of CVD
events being 9.7 (95% 8.9-10.6) per 1000 person: women
7.3 (6.4-8.3) and men 13.0 (11.7-14.6).
Participants’ characteristics are shown according to
baseline VAI quintiles in Tables 1 and 2. In general, CVD
risk factors levels at baseline increased in stepwise fashion
across VAI quintiles; except for smoking. The annual inci-
dence rate of CVD events showed an increasing trend
across quintiles of VAI among women (P < 0.001). Age-
adjusted survival functions for quintiles of VAI have been
compared in Figures 1 and 2. Age-adjusted CVD-free sur-
vival probability decreased significantly across VAI quin-
tiles among both men and women (P values < 0.001).
Risk of future CVD increased with increasing levels of
VAI among both men and women. Among women, but
not men, the increased risk resisted adjustments for
t h eC V Dr i s kf a c t o r s( T a b l e3 ) .A ss h o w ni nT a b l e3 ,
HRs for CVD of WHpR and WHtR were consistently
higher than those of VAI among both men and women.
These superiorities, however, did not reach statistical
significance.
We observed that among men, 0.7% (95% CIs 0.09-1.9%)
of variations in CVD-free survival time was explained VAI.
The corresponding figures were 4.5% (95% CIs 2.4-7.2%)
for WHtR, 6.1 (95% CIs 3.6-9.0%) for WHpR, and 0.8%
(95% CIs 0.1-2.2%) for BMI. Among women, 5.0% (95%
CIs 2.7-7.8%) of variations in CVD-free survival time was
explained VAI. The corresponding figures were 7.3% (95%
CIs 4.5-10.7%) for WHtR, 10.0 (95% CIs 6.6-13.9%) for
WHpR, and 1.4% (95% CIs 0.4-3.0%) for BMI.
Harrell’s C (95% CIs) and Nam-D’Agostino c
2 (P for
lack of fit) for the CVD risk based on the Framingham
general CVD algorithm were 0.777 (0.754-0.802) and
15.8 (0.070) among men; the corresponding figures were
0.778 (0.704-0.802) and 13.6 (0.135) for VAI, 0.712
(0.700-0.729) and 12.2 (0.200) for BMI, 0.778 (0.704-
0.802) and 17.0 (< 0.0.048) for WHtR, and 0.778 (0.704-
0.802) and 14.6 (0.103) for WHpR. The Harrell’s C (95%
CIs) and NamD’Agostino c
2 (P for lack of fit) for the
CVD risk based on the Framingham general CVD
Table 1 Basal characteristics of participants across VAI quintiles, among men
Q1 Q2 Q3 Q4 Q5
N = 658 N = 563 N = 614 N = 475 N = 464 P for trend
VAI range 0.27-1.49 1.49-2.26 2.26-3.24 3.24-4.88 4.89-29.84
Age (years) 41.43 (10.86) 45.18 (11.36) 47.70 (11.80) 48.30 (11.64) 49.79 (11.11) 0.010
Life style modification 263 (0.4) 220 (0.39) 221 (0.36) 185 (0.39) 190 (0.41) 0.764
Smoking 184 (0.28) 157 (0.28) 177 (0.29) 132 (0.28) 144 (0.31) 0.451
Diabetes 32 (0.05) 44 (0.08) 66 (0.11) 89 (0.19) 100 (0.22) < 0.001
Anti-hypertensive drug 46 (0.07) 39 (0.07) 43 (0.07) 38 (0.08) 32 (0.07) 0.720
SBP (mm Hg) 113.73 (16.81) 119.67 (18.71) 123.54 (20.84) 126.18 (21.21) 129.35 (21.43) < 0.001
DBP (mm Hg) 74.98 (9.81) 78.03 (10.26) 80.16 (10.90) 81.35 (10.73) 82.83 (10.62) < 0.001
Weight (kg) 64.06 (10.95) 67.41 (12.08) 69.62 (11.33) 71.27 (12.43) 72.12 (11.18) < 0.001
Waist (cm) 82.01 (10.83) 87.93 (11.67) 91.12 (10.95) 93.68 (11.31) 96.31 (10.17) < 0.001
Height (cm) 156.46 (5.78) 156.13 (6.11) 155.25 (5.69) 155.54 (5.92) 155.27 (5.76) < 0.001
Hip circumference (cm) 102.24 (8.78) 104.40 (9.34) 106.00 (9.59) 106.77 (9.50) 106.82 (9.14) < 0.001
BMI (kg.m
-2) 26.20 (4.50) 27.66 (4.73) 28.90 (4.58) 29.42 (4.63) 29.90 (4.25) < 0.001
WHpR 80.16 (7.37) 84.20 (7.97) 86.01 (7.52) 87.77 (7.74) 90.30 (7.50) < 0.001
WHtR 52.51 (7.40) 56.42 (7.93) 58.77 (7.43) 60.29 (7.43) 62.10 (6.81) < 0.001
TC (mmol.l
-1) 5.07 (0.96) 5.39 (1.03) 5.76 (1.07) 5.97 (1.15) 6.30 (1.35) < 0.001
HDL-C (mmol.l
-1) 1.43 (0.27) 1.28 (0.25) 1.16 (0.21) 1.06 (0.19) 0.91 (0.18) < 0.001
TGs (mmol.l
-1) 0.86 (0.21) 1.28 (0.28) 1.70 (0.34) 2.19 (0.44) 3.59 (1.38) < 0.001
Ln-TGs -0.19 (0.26) 0.23 (0.21) 0.51 (0.20) 0.76 (0.20) 1.22 (0.32) < 0.001
FPG (mmol.l
-1) 5.01 (1.17) 5.26 (1.55) 5.53 (2.00) 5.91 (2.46) 6.23 (2.59) < 0.001
PCPG (mmol.l
-1) 5.79 (1.76) 6.25 (2.16) 6.94 (3.18) 7.56 (3.35) 8.35 (3.90) < 0.001
Incident CVD 9.7 (7.4-12.6) 13.9 (10.9-17.7) 12.3 (9.7-15.8) 15.3 (11.9-19.7) 15.2 (11.8-19.7) 0.076
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; MAP,
mean arterial pressure; PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TGs, triglycerides; VAI, visceral adiposity
index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio
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Q1 Q2 Q3 Q4 Q5
N = 654 N = 718 N = 677 N = 793 N = 783 P for trend
VAI range 0.26-1.49 1.49-2.25 2.26-3.24 3.24-4.87 4.88-46.74
Age (years) 49.11 (14.46) 48.5 (13.32) 48.27 (12.78) 48.46 (12.55) 46.97 (11.87) < 0.001
Life style modification 250 (0.38) 285 (0.40) 256 (0.38) 315 (0.40) 303 (0.39) 0.874
Smoking 26 (0.04) 21 (0.03) 32 (0.05) 26 (0.03) 28 (0.04) 0.846
Diabetes 22 (0.03) 47 (0.07) 86 (0.13) 150 (0.20) 202 (0.27) < 0.001
Anti-hypertensive drug 53 (0.08) 101 (0.14) 121 (0.18) 151 (0.19) 197 (0.25) < 0.001
Lipid lowering drug 7 (0.01) 11 (0.02) 16 (0.02) 44 (0.06) 98 (0.13) < 0.001
SBP (mm Hg) 120.28 (20.67) 121.48 (21.20) 123.49 (19.52) 123.22 (16.87) 124.92 (18.51) < 0.001
DBP (mm Hg) 75.91 (11.83) 77.66 (11.57) 79.79 (11.60) 80.03 (10.27) 80.73 (11.31) < 0.001
Weight (kg) 67.94 (11.85) 73.70 (11.28) 76.37 (11.45) 78.47 (11.72) 80.30 (11.53) < 0.001
Waist (cm) 82.91 (10.83) 88.91 (10.01) 91.64 (9.58) 93.85 (9.29) 95.69 (8.85) < 0.001
Height (cm) 168.79 (7.05) 169.09 (6.48) 169.11 (6.48) 168.74 (5.93) 169.34 (6.70) < 0.001
Hip circumference (cm) 93.12 (6.73) 96.22 (6.62) 97.41 (6.06) 98.36 (6.67) 99.05 (6.50) < 0.001
BMI (kg.m
-2) 23.84 (3.85) 25.79 (3.79) 26.67 (3.45) 27.52 (3.54) 27.97 (3.39) < 0.001
WHpR 88.81 (7.17) 92.26 (6.50) 93.96 (6.28) 95.35 (6.01) 96.59 (6.20) < 0.001
WHtR 49.20 (6.67) 52.67 (6.41) 54.24 (5.77) 55.65 (5.43) 56.56 5.37 () < 0.001
TC (mmol.l
-1) 4.94 (0.98) 5.36 (0.99) 5.50 (1.01) 5.63 (1.07) 5.87 (1.15) < 0.001
HDL-C (mmol.l
-1) 1.22 (0.26) 1.04 (0.18) 0.95 (0.17) 0.87 (0.16) 0.77 (0.15) < 0.001
TGs (mmol.l
-1) 0.98 (0.26) 1.51 (0.28) 2.01 (0.39) 2.62 (0.50) 4.35 (1.63) < 0.001
Ln-TGs -0.06 (0.28) 0.39 (0.19) 0.68 (0.19) 0.95 (0.19) 1.41 (0.32) < 0.001
FPG (mmol.l
-1) 5.26 (1.44) 5.26 (1.17) 5.47 (1.64) 5.80 (1.98) 6.07 (2.34) < 0.001
PCPG (mmol.l
-1) 5.80 (2.79) 6.08 (2.77) 6.61 (3.18) 7.09 (4.01) 7.66 (4.01) < 0.001
Incident CVD 2.4 (1.4-4.1) 3.9 (2.7-5.8) 6.3 (4.5-8.7) 10.7 (8.5-13.5) 11.9 (9.5-14.8) < 0.001
BMI, body mass index; CVD, cardiovascular disease; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; MAP,
mean arterial pressure; PCPG, 2-hour post-challenge plasma glucose; SBP, systolic blood pressure; TC, total cholesterol; TGs, triglycerides; VAI, visceral adiposity
index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio
Figure 1 Age-adjusted survival curves across quintiles of the visceral adiposity index: men.
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Page 5 of 10algorithm were 0.841 (0.820-0.862) and 13.9 (0.126)
among women. The corresponding figures were 0.841
(0.820-0.862) and 11.1 (0.266) for VAI, 0.835 (0.814-
0.858) and 35.9 (< 0.001) for BMI, 0.838 (0.816-0.859)
and 42.0 (< 0.0001) for WHtR, and 0.839 (0.8170.860)
and 23.2 (0.005) for WHpR.
As shown in Table 4, VAI failed to add to the predic-
tive ability of the Framingham general CVD algorithm.
Moreover, among women, when VAI was directly com-
pared to the WHtR, WHpR, and BMI, NRI and IDI sta-
tistics were negative, indicating that WHpR, WHtR, and
BMI predicted CVD better than did VAI. The only
exception insinuated to the findings was that, among
men, VAI outperformed BMI as denoted by all indices
of added predictive abilities.
Multivariate restricted cubic splines regression analysis
demonstrated that VAI-CVD dose- response relations
had no threshold and yielded straight lines when risk of
disease was plotted on a logarithmic scale (Figure 3).
The incident CVD risk corresponding to VAI = 2.3 was
null; above this value VAI conferred hazard for incident
CVD in a linear fashion. VAI values below 2.3 appeared
to provide some protection against CVD.
HRs for incident CVD of lifestyle modification inter-
vention measures was 0.89 (95% CIs 0.70-1.12, P value
= 0.324) among men and 1.11 (95% 0.85-1.45, P value =
0.435) among women. Intervention measures did not
contribute to the risk of CVD; neither did the interven-
tion measures modify the effects of VAI on the risk of
incident CVD (P for interaction: men 0.304 and women
0.711).
VIFs were all < 10 and therefore collinearity did not
appear to be a problem.
Figure 2 Age-adjusted survival curves across quintiles of the visceral adiposity index: women.
Table 3 Hazard ratios for incident CVD of VAI vs. WHpR
and WHtR
HR 95% CIs vs. VAI
a
Men VAI 1.18 (1.07-1.30) -
WHpR 1.37 (1.22-1.55) 0.061
WHtR 1.38 (1.21-1.58) 0.068
BMI 1.28 (1.13-1.45) 0.355
Age-adjusted Women VAI 1.27 (1.18-1.37) -
WHpR 1.52 (1.31-1.76) 0.133
WHtR 1.45 (1.27-1.66) 0.229
BMI 1.26 (1.12-1.43) 0.682
Men VAI 1.05 (0.94-1.18) -
WHpR 1.23 (1.07-1.40) 0.078
WHtR 1.21 (1.05-1.39) 0.123
BMI 1.08 (0.95-1.23) 0.301
Multivariate-adjusted
b, c Women VAI 1.17 (1.07-1.28) -
WHpR 1.42 (1.22-1.65) 0.078
WHtR 1.36 (1.18-1.56) 0.146
BMI 1.04 (1.01-1.07) 0.352
CVD, cardiovascular disease; HR, hazard ratio; VAI, visceral adiposity index;
WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio
a. P values were derived from Wald tests of the linear hypotheses concerning
the Weibull regression models coefficients (paired homogeneity test). As such,
we tested the null hypotheses that the hazard ratios (effect size) for VAI were
equal to those for WHpR, WHtR, or BMI
b. Adjusted for the effects of age, systolic blood pressure, anti-hypertensive
medication use, total and high-density lipoprotein cholesterol, diabetes, and
smoking
c. To avoid over-adjustment, VAI was not adjusted for high-density lipoprotein
cholesterol since it was a component of VAI
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In this prospective cohort of men and women, we found
associations between higher VAI and risk of incident
CVD as compared to simple, commonly available
anthropometric measures. This community-based study
demonstrated that a 1-SD increase in VAI carries 18-
27% increase in age-adjusted risk of future CVD. After
adjustment for traditional CVD risk factors however, it
was only among women that VAI retained its predict-
ability for incident CVD events. VAI failed to add to the
predictive ability of the Framingham’s “general CVD
algorithm,” neither it did so to those of BMI, WHpR, or
WHtR. The interesting finding of our study was that
using VAI instead of simple anthropometric measures of
adiposity may lead to loss of considerable information
needed for predicting incident CVD. WHtR and WHpR
explained greater part of variations in the CVD-free sur-
vival time than VAI did.
Establishing the shape of associations between risk fac-
tors and CVD is important to gauge the potential for pre-
vention [22,23]. We observed that dose-response
association between VAI and CVD risk had no threshold.
The incident CVD risk corresponding to the VAI = 2.3
was null. However, the slope of the dose-response
association was steeper for VAI values smaller than 2.3
than those greater than 2.3. VAI values below 2.3 appeared
to provide some protection against CVD. Above this value
VAI conferred hazard for incident CVD in a linear fashion.
As such, irrespective of the level of the VAI, a given
increase in VAI levels above 2.3 would be accompanied by
t h es a m ep r o p o r t i o n a li n c r e a s ei nr i s ko fi n c i d e n tC V D
regardless of the initial risk. Meanwhile, a given decrease
in VAI levels below 2.3 would be accompanied by the
same proportional reduction in risk of incident CVD
regardless of the initial risk. Our findings support previous
reports showing the best cut-off point for VAI to be
around 2.2 [24].
Adjusting for potential intermediates in the association
between adiposity and CVD generally attenuates relative
risks for the various indices [25,26]. We observed that
after adjustment for CVD risk factors, men’sV A Il e v e l s
were no longer associated with risk of incident CVD.
Moreover, VAI did not improve the predictive ability of
the Framingham general CVD risk prediction rule;
WHtR and in particular WHpR were both superior to
VAI in predicting risk of incident CVD, particularly
among women. We also estimated the improvements
across different categories of risk of the Framingham risk
Table 4 Added predictive ability conferred by VAI. male
Women Men
95% CIs P-value Statistic 95% CIs P-value
General CVD risk
b
Absolute IDI (%) -0.005 -0.009 -0.002 0.004 -0.003 -0.006 -0.001 0.006
Relative IDI (%) -0.039 -0.064 -0.014 0.002 -0.025 -0.042 -0.007 0.005
Cut-point-based NRI
c (%) -0.018 -0.053 0.017 0.310 -0.004 -0.028 0.021 0.764
Cut-point-free NRI (%) -0.221 -0.354 -0.089 0.001 -0.173 -0.258 -0.089 0.000
WHtR
Absolute IDI (%) -0.044 -0.054 -0.035 0.000 -0.017 -0.022 -0.012 0.000
Relative IDI (%) -0.262 -0.298 -0.225 0.000 -0.115 -0.147 -0.084 0.000
Cut-point-based NRI
c (%) -0.077 -0.141 -0.013 0.019 -0.008 -0.042 0.025 0.632
Cut-point-free NRI (%) -0.052 -0.140 0.036 0.250 0.010 -0.070 0.091 0.800
WHpR
Absolute IDI (%) -0.028 -0.037 -0.020 0.000 -0.012 -0.017 -0.008 0.000
Relative IDI (%) -0.185 -0.228 -0.142 0.000 -0.085 -0.113 -0.057 0.000
Cut-point-based NRI
c (%) -0.027 -0.084 0.030 0.345 0.003 -0.030 0.035 0.878
Cut-point-free NRI (%) -0.177 -0.294 -0.060 0.003 -0.122 -0.207 -0.037 0.005
BMI
Absolute IDI (%) -0.038 -0.047 -0.029 0.000 0.055 0.042 0.068 0.000
Relative IDI (%) -0.233 -0.270 -0.197 0.000 0.727 0.481 0.973 0.000
Cut-point-based NRI
c (%) -0.067 -0.125 -0.010 0.022 0.346 0.286 0.406 0.000
Cut-point-free NRI (%) -0.031 -0.120 0.059 0.501 0.507 0.423 0.592 0.000
BMI, body mass index; CVD, cardiovascular disease; IDI, integrated discrimination improvement index; NRI, net reclassification improvement index; VAI, visceral
adiposity index; WHpR, waist-to-hip ratio; WHtR, waist-to-height ratio
a. Negative signs indicate less predictive ability for VAI as compared to the general CVD algorithm, WHtR, WHpR, or BMI
b. Calculated in accordance with D’Agostino, R.B., Sr., et al., General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study. Circulation,
2008. 117(6): p. 743-753
For cut-point based NRI, the cut-points were set at 0.05, 0.1, and 0.2 of estimated risk
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one percent of participants with moderate CVD risk were
correctly reclassified (data are available upon the
request). It has been shown that measures of adiposity
are correlated with cardiovascular risk although no single
adiposity measure can be identified as the best predictor
[27]. In line with our findings, however, WHtR and
WHpR have been shown to be superior to BMI [28-31].
Across quintiles of VAI, contribution of WHtR and
WHpR to risk of incident CVD remained essentially the
same (data available upon the request from authors);
indicating that VAI did not modify effects of these risk
factors on the risk of CVD. The finding that VAI was not
better than WHpR or WHtR, at least in part, could possi-
bly be explained by high correlation between WHpR
and WHtR and components of VAI i.e. BMI, waist
circumference, HDL-C, and TGs [32]. Anthropometric
measures were previously demonstrated to keep pace
with a combination of TGs and waist circumference,
“lipid accumulation product,” in predicting incident CVD
[5]. Technological developments including computer
tomography scans and MRI, made it possible to precisely
measure specific adipose tissue depots such as visceral
a d i p o s et i s s u em a s s[ 3 3 ] .W ea r ea w a r eo fo n ep r o s p e c -
tive study in which visceral adiposity mass has directly
been measured and compared to its anthropometric
indices with respect to the CVD prediction [34]. Interest-
ingly, clinical measurements of abdominal obesity were
reported to be better predictors of CVD progression than
tomography assessment in women [34]. These findings
underscore the fact that there is so much room for inves-
tigations on adiposity measures that could improve CVD
prediction above and beyond what have already been
achieved by simple anthropometric measures.
The hypothesis that visceral adiposity would explain
more variance in CVD risk factors than general adiposity
was not supported in a relatively large sample of black
and white adolescents [35].
“Is the visceral adiposity worth the trouble or expenses
involved in accurate measurements for prediction of
future CVD?” While current evidences point to the
importance of using clinical measurements of abdominal
obesity to identify individuals at increased risk for athero-
sclerosis [34], evidences are not firm enough to
Figure 3 Non-linear contribution of the visceral adiposity index to the risk of incident cardiovascular disease.
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Page 8 of 10recommend precise measurement of the visceral adipos-
ity mass for predicting incident CVD [27]. Moreover,
Moebus et al. have demonstrated that the importance of
different combinations of metabolic syndrome changes
with age and between sexes putting emphasis on a tai-
lored approach towards very young or very old subjects
[36]. Sex- and age-specific VAI, thus, may confer stron-
ger predictive capacity.
Strengths of the present study lie in its prospective nat-
ure, the use of a large population-based-cohort of both
sexes, accurate and valid data on risk factors at baseline,
continuous surveillance of mortality and CVD events
based on standard criteria.
Some limitations to our study merit mentioning. First, in
this study, no data was available about TGs lowering
drugs. Second, the population studied was of Persian
ancestry, our results, thus, cannot be readily extrapolated
to other populations. The debate over how best to define
visceral adiposity is complicated by observations suggest-
ing that surrogates of adiposity may each perform better
in predicting CVD risk in specific populations, depending
on sex, age, and ethnicity [1].
Conclusion
We demonstrated that the VAI was independently asso-
ciated with an increased risk of incident CVD among
women and that the magnitude of this risk due to VAI
was not significantly higher than those due to BMI,
WHpR, or WHtR. However, among men, after controlling
common CVD risk factors, we observed that VAI was not
associated with any significant increased risk of incident
CVD. The increased risk observed among women, how-
ever, resisted all adjustment. Using VAI instead of simple
anthropometric measures of adiposity may lead to loss of
considerable information needed for predicting incident
CVD.
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